Craniomaxillofacial Device is anticipated to have CAGR of ~6.1% over 2019-2028. Craniomaxillofacial Implants are the accessories that are used for the cranial/head, oral, neck, face, and jaw surgeries. The deformity in the maxillary, cranial, facial region may be caused due to accidents, or even congenital facial disorders. The key factors that are anticipated to propel the industry include, increase in the rate of the incidence of the congenital deformities such as Cleft palate in the forecast period. The rise in the cases of trauma and the road accidents statistics getting increased would help the industry fuel in the coming years.
Top Driver: Increase in the number of road accidents to boost the industry
Craniomaxillofacial Device is projected to grow with the surge in the number of individuals experiencing road accidents. According to the statistics given by the Association for Safe International Road Travel, about 20-50 million injuries which are taking place due to road accidents, hence propelling the Craniomaxillofacial devices industry in the forecast period. There is a growth in demand for minimally invasive surgical procedures for improving aesthetics for those facing injuries or facial disorders. This would help the industry boost in the coming years. The American Society of the Plastic Surgeons, about 15.9 million minimally invasive technique based plastic surgeries were performed in 2018 and is anticipated to flourish due to the surge in the demand of the minimally invasive procedures over traditional method.
Neurosurgery and ENT to Make Crucial Contribution to Growth of Global Craniomaxillofacial Device Market
Among application segments of the global Craniomaxillofacial Device market, Neurological and ENT Diseases segment to gain highest revenue shares in the forecast period. This is due to the surge in the incidence of trauma and spinal disorders, which requires Cerebrospinal Fluid (CSF) management during surgery. Furthermore, the key surgeons perform craniotomies to have greater access to the brain during the neurosurgery. Craniotomies is the process that are done to treat trauma, infection in brains, aneurysm, skull fractures, pressure in the brain after a stroke or an injury, and to remove blood clots from a head injury. The Craniomaxillofacial devices are required for the further surgeries so that the end results are gained as predicted. The Plastic surgery segment is anticipated to gain highest CAGR due to the growth in demand for better aesthetics in the forecast period.
to Benefit North America Market
North America is experiencing highest revenue growth than any other country and is anticipated to boost further in the coming years. This is owes to the surge in incidence of facial deformities and facial fractures, caused due to rise in the industrialization. Furthermore, there is introduction of technologically advanced cranial implants, and the increase in demand for minimally invasive surgeries in the North American region, which is anticipated to boost the industry in the near future. The availability and growing sophisticated healthcare infrastructure, and boosting patient awareness levels would help the industry flourish. The Asia Pacific region is anticipated to gain highest CAGR, due to the presence of untapped opportunities, and also improvement in the healthcare infrastructure, are attributed to market growth.
Due to outbreak of COVID-19 the Craniomaxillofacial Device is anticipated to experience downfall. This owes to the shut-down of operations of major hospitals, to avoid spread of the infectons acquired through hospitals.
Players to Focus on Craniomaxillofacial Device
The global Craniomaxillofacial Device market leaders include Cavendish Implants Ltd., CONMED Corporation, Integra Life Sciences, B. Braun Melsungen AG (Aesculap Implant Systems, Inc.), Johnson and Johnson, KLS Martin L.P., Medtronic, OsteoMed, Medartis AG, Stryker Corporation, TMJ Concepts, Zimmer Biomet Holdings, Inc.
Johnson & Johnson Medical Devices Companies: In February 2018, Johnson & Johnson Medical Devices Companies, through French affiliate Apsis S.A.S., announced the acquisition of Orthotaxy, a privately-held developer of software-enabled surgery technologies, including a differentiated robotic-assisted surgery solution. This proprietary technology is currently in early-stage development for total and partial knee replacement, and the Johnson & Johnson Medical Devices Companies plan to broaden its application for a range of orthopaedic surgery procedures.
ConMed: In July 2018, ConMed inked a deal to acquire surgical smoke evacuation tech developer Buffalo Filter for $365 million. Buffalo Filter develops and produces surgical smoke evacuation technologies, including smoke evacuation pencils, smoke evacuators and laparoscopic solutions,
Integra LifeSciences Holdings Corporation: In July 2019, Integra LifeSciences Holdings Corporation, a leading global medical technology company, today announced that it has acquired Arkis Biosciences Inc. a privately-held company that offers a portfolio of neurosurgical devices, including the CerebroFlo external ventricular drainage (EVD) catheter with Endexo technology, a permanent additive designed to reduce the potential for catheter obstruction due to thrombus formation. The acquisition of Arkis Biosciences strengthens Integra’s offerings in neurocritical care and Integra’s position as the world leader in advanced catheter technology.
Scope of the Report
Key Reasons to Purchase this Report
Table of Content
Please fill out the form to receive sample pages of the report